ViziLite Oral Cancer Screeining

  

ViziLite® Plus with TBlue

 

What is Vizilite?

 

ViziLite Plus with TBlue is oral lesion identification and marking system that is used as in conjuctuin with conventional head and neck examination to identify, evaluate, monitor and mark abnormal oral lesions suspicious for pathology including precancerous cells and cancer that may be difficult to see during a regular visual exam.

 

It is comprised of a chemiluminescent light source to improve the identification of lesions and a blue phenothiazine dye to mark those lesions identified by ViziLite.

 

ViziLite Plus with TBlue is designed to be used with patients at risk for oral cancer.

 

ViziLite can assist a dentist or hygienist in identifying an abnormality in the oral cavity.

 

Why use it?

  

Early Detection is Critical

Your patients rely on you to be an expert in oral health.

 

Dentists and hygenists are the best overall defense against oral cancer — you are, in fact, a lifesaver.

 

No other medical professionals are as well positioned to address this potentially deadly disease at its earliest stage.

  

The key is to identify oral abnormalities at their most easily treated stage of development.

 

ViziLite Plus aids in the early identification of oral abnormalities that can lead to cancer.

  

 How does it work?

 

After rinsing with a dilute acetic acid solution, abnormal squamous epithelium tissue will appear acetowhite when viewed under ViziLite’s diffuse low-energy wavelength light.

 

Normal epithelium will absorb the light and appear dark.

Normal epithelium absorbs ViziLite illumination

Abnormal epithelium: leukoplakias appear white; red lesions appear darker than surrounding tissue

 

TBlue is a patented, pharmaceutical-grade toluidine blue-based metachromatic dye. It is used to further evaluate and closely monitor changes in ViziLite-identified lesions.

 

TBlue, in an easy to use 3-swab system, providing the deep blue staining that allows ViziLite-identified lesions to be seen clearly under normal light.

 

The ViziLite® Plus exam is performed with the following materials:

• One disposable ViziLite light stick

• A ViziLite retractor

• 30ml ViziLite acetic acid solution (raspberry flavor)

• TBlue®Oral Lesion Marking System (one acetic acid swab, one TBlue swab, one acetic acid swab)

• One dosing cup

• Reproducible patient consent/waiver form with exam documentation map and instructions

 

How to use:

 

Following are instructions for identifying abnormal oral tissue using the ViziLite® Plus with TBlue oral lesion identification and marking system:

 

1. ENCOURAGE PATIENTS to read the ViziLite Plus patient education brochure. Once the patient is in the operatory, document patient authorization by putting the signed Patient Consent/Waiver Form (provided) in chart. 

  

2. CONDUCT ROUTINE EXAM of the oral cavity, noting the presence of any lesions.

  

3. HAVE PATIENT RINSE with ViziLite Pre-Rinse solution (1% acetic acid) for 30-60 seconds.

  

4.  While patient is swishing BEND FLEXIBLE outer light stick, breaking brittle inner vial.

  

5. SHAKE VIGOROUSLY to mix contents of light stick. Insert light stick into open end of retractor and assemble.

  

6. Turn off lights in operatory close the blinds and shade subject as much as possible. If you are unable to dim the room lighting, you can use eye wear provided by ViziLite Plus to facilitate the examination.

 

 Both patient and operator should where special goggles to protect eyes.

 

7. RE-EXAMINE the oral cavity using ViziLite device. The open retractor window should face the tissue being examined.

 

Place light in the mouth, if oral cancer is present you will see a spot show up lighter than the other surrounding tissues.

 

Look at the cheeks, tongue, dorsal of tongue, soft palate, hard palate, lips, floor of the mouth, throat, after a through check go over same areas again.

 

8. LOOK FOR AND DOCUMENT any abnormalities you see on the mouth map located on the back of the patient consent form. Apply the TBlue marking system to lesions visible under ViziLite illumination. Swabs should be applied in sequential order. The swab tubes are individually labeled 1, 2, and 3.

 

Measure the lesion or lesions and record in patients chart also.

 

9. LESIONS STAINED WITH TBLUE can be viewed clearly even without the ViziLite device.

 

If possible, photograph the lesion or take an intra-oral photograph for inclusion in the patient record, submission to the patient’s insurance carrier, or for referral to a specialist.

 

10. Discard all components.

 

ViziLite Plus Oral Screening Protocol:

 

ViziLite Plus should be offered annually to all new and re-care adult patients following the standard head and neck exam. Patients with a history of oral cancer should receive at least semi-annual ViziLite Plus exams.

 

As is the case with most cancers, age is the primary risk factor for oral cancer. Approximately 90% of oral cancer victims are age 40 and older, recent studies indicate that increasingly, patients younger than age 40 are being diagnosed with oral cancer.

 

Though tobacco and alcohol use are the primary lifestyle risk factors that contribute to the development of oral cancer, 25% of oral cancer victims do not use tobacco or alcohol, and have no lifestyle risk factors.

 

Oral cancer affects men more than women, 2:1, but oral cancer in women is on the rise nationwide.

 

Annual ViziLite Plus exams can be integrated with exsisting patient services, improving patient care and creating a positive financial impact in dental practices.

http://www.vizilite.com/vizilite_exam/

 

slide show : http://vizilitetraining.com/zila_content.html About 20 minutes

 

http://vizilitetraining.com/

 

http://www.zila.com/40/VIZILITE%26REG%3B%20PLUS/

Comments are closed.